Promoters

Patent metadata

Field	Value
Publication number	US-11261464-B2
Application number	US-201715706892-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Sep 20, 2016
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

First claim

What is claimed is:

1. A promoter sequence comprising sequences having at least 95% sequence identity and/or homology to SEQ ID NO: 1 (4pgG600), SEQ ID NO. 2 (4pMCP600), SEQ ID NO. 3 (p430), SEQ ID NO: 4 (p455), or the complementary nucleotide sequences thereof, wherein said promoter sequence is operably linked to a heterologous nucleotide sequence of interest, a gene of interest, and/or an antigen encoding sequence of interest.

2. The promoter sequence of claim 1 , wherein the promoter sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and the complementary nucleotide sequences thereof.

3. An expression cassette comprising a promoter sequence selected from the group consisting of sequences having at least 95% sequence identity and/or homology to SEQ ID NO. 1 (4pgG600), SEQ ID NO. 2, (4pMCP600), SEQ ID NO. 3 (p430), SEQ ID NO: 4 (p455), and the complementary nucleotide sequences thereof,
wherein the promoter sequence is operably linked to a nucleotide sequence of interest,
wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence.

4. The expression cassette of claim 3 , wherein the promoter sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and the complementary nucleotide sequences thereof.

5. A vector comprising the expression cassette according to claim 3 .

6. The vector according to claim 5 , whereby said vector is a recombinant vector, and/or a heterologous vector, and/or an exogenous vector.

7. The vector according to claim 5 , whereby said vector is a viral vector, selected from the group consisting of: Herpesviridae, Varicelloviruses, Adenoviridae (AdV), Adena-associated viridae, Baculoviridae, Lentiviridae.

8. The vector according to claim 5 , whereby said viral vector is a member of the family Herpesviridae, and/or of the genus Alphaherpesvirinae, and/or of the subgenus Varicellovirus , and/or is Equid Alphaherpesvirus 1 (EHV-1).

9. The vector according to claim 5 , whereby said vector comprises one or more further regulatory sequences, a polyadenylation signal, an IRES regulatory element, and/or a 2a peptide regulatory element.

10. An eukaryotic host cell line comprising a vector comprising a promoter sequence selected from the group consisting of sequences having at least 95% sequence identity and/or homology to SEQ ID NO. 1 (4pgG600), SEQ ID NO. 2 (4pMCP600), SEQ ID NO. 3 (p430), SEQ ID NO: 4 (p455), and the complementary nucleotide sequences thereof,
wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of: a gene of interest, a heterologous and/or exogenous sequence of interest, or an antigen encoding sequence of interest,
wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
wherein said host cell line is a mammalian cell line or an insect cell line, selected from the group consisting of: a PK/WRL cell line, a RK13 cell line, a MDBK cell line, a ST cell line, an AI-ST cell line, a VERO cell line, a Sf9 cell line, a Sf21, a Sf plus cell line, a MDCK cell line, and/or derivatives thereof.

11. A kit comprising
a. a host cell(s),
b. optionally a transfection reagent(s),
c. an instruction leaflet, and
d. a vector comprising a promoter sequence selected from the group consisting of sequences having at least 95% sequence identity and/or homology to SEQ ID NO. 1 (4pgG600), SEQ ID NO. 2 (4pMCP600), SEQ ID NO. 3 (p430), SEQ ID NO: 4 (p455), and the complementary nucleotide sequences thereof,
wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of: a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence.

12. A method of producing a vector, comprising
a. providing a promoter sequence comprising SEQ ID NO: 1 (4pgG600), SEQ ID NO. 2 (4pMCP600), SEQ ID NO. 3 (p430), SEQ ID NO: 4 (p455), or the complementary nucleotide sequences thereof, wherein said promoter sequence leads to expression of a nucleotide sequence of interest, and/or an antigen encoding sequence of interest,
b. integrating said promoter sequence of step a) into a vector backbone derived from a virus, which is selected from the group consisting of: Herpesviridae, varicelloviruses, Adenoviridae (AdV), Parvoviridae like Adena-associated viruses, Baculoviridae, Retroviridae, and Poxviridae.

13. A method of preparing a host cell, comprising:
a) infecting a permissive eukaryotic host cell line with a vector comprising a promoter sequence selected from the group consisting of SEQ ID NO: 1 (4pgG600), SEQ ID NO: 2 (4pMCP600), SEQ ID NO: 3 (p430), SEQ ID NO: 4 (p455), and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of: a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
wherein said promoter sequence leads to expression of the nucleotide sequence of interest, whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
b) cultivating the infected cells of a) under suitable conditions, and
c) optionally harvesting said host cell.

14. A method for the preparation of an immunogenic composition or a vaccine for reducing the incidence or the severity of one or more clinical signs associated with or caused by an infection, comprising the following steps:
a) infecting a permissive eukaryotic host cell line with a vector comprising a promoter sequence selected from the group consisting of SEQ ID NO: 1 (4pgG600), SEQ ID NO. 2 (4pMCP600), SEQ ID NO. 3 (p430), SEQ ID NO: 4 (p455), and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of: a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
b) cultivating the infected cells of a) under suitable conditions,
c) harvesting infected cells of b) and/or vector and/or virus components,
d) optionally purifying the harvest of step c), and
e) admixing said harvest with a pharmaceutically acceptable carrier.

Assignees

• Boehringer Ingelheim Vetmedica Gmbh

Inventors

• Mundt Alice
• Gallei Andreas
• Koukuntla Ramesh
• Mandell Robert Barry
• REHMET Kristina
• Vaughn Eric Martin

Classifications

• C12N15/85 Primary

  for animal cells · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2710/00045

  Special targeting system for viral vectors · CPC title

• C12N15/86

  Viral vectors · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title